{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7","upperLimit":"100","value":"16"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"28"}],"units":"Participants"}],"description":"determined by RECIST 1.1.","dispersionType":"90% Confidence Interval","groups":[{"description":"This is an MSKCC investigator-initiated, single-center, non-randomized, open-label, phase II study to evaluate the activity of LY3023414 dosed at the RP2D of 200 mg orally twice daily in patients with recurrent or persistent endometrial cancer.\n\nLY3023414: Enrolled patients will take LY3023414 200 mg orally twice a day. Each cycle will be 21 days in duration. Patients will receive study treatment until disease progression, intolerable toxicity, elective withdrawal from the study, study completion, or study termination","id":"OG000","title":"LY3023414"}],"paramType":"MEAN","reportingStatus":"POSTED","timeFrame":"1 year","title":"Overall Response Rate","type":"PRIMARY","unitOfMeasure":"percentage of participants"}